LeonaBio, Inc.

Stage 4 · Declining · week 5

As of Oct 22, 2026, LeonaBio is in Stage 4, the downtrend phase, now in week 5 (since Sep 21, 2026). It closed at $4.97, 57.4% below its 52-week high and below its 200-day average, which is falling.

$4.97

-12.35% today

$46.8M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is LONA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 18w

S4 20w

S2 33w

S3 13w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 1w → S4 18w → S1 6w → S2 8w → S3 6w → S4 5w → S1 3w → S2 9w → S3 1w → S4 12w → S1 7w → S4 20w → S1 13w → S2 3w → S3 3w → S2 33w → S3 13w → S4 5w current

Total tracked: 165 weeks across 18 stage runs.

LONA among Biotechnology144th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…144	LONALeonaBio, Inc.	Stage 4 · wk 5	67	−15.6%

vs 52W High

-57.4%

$2.87 lo$11.68 hi

57.4% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 5

1w13w26w

Week 5, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-34.3%

200 DMA: $7.57 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.21x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-15.6%

-32.7%

-42.3%

YTD

-28.6%

+16.7%

Scan Membership

Breakout Watch

Latest: 2024-07-09

3 appearances in last 60 days. First seen: 2022-01-03.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 5 · Vol 0.21x

2026-10-21S4

Wk 5 · Vol 0.04x

2026-10-20S4

Wk 5 · Vol 0.26x

2026-10-19S4

Wk 5 · Vol 0.17x

2026-10-16S4

Wk 4 · Vol 0.26x

2026-10-15S4

Wk 4 · Vol 0.15x

2026-10-14S4

Wk 4 · Vol 0.44x

2026-10-13S4

Wk 4 · Vol 0.25x

2026-10-12S4

Wk 4 · Vol 1.71x

2026-10-09S4

Wk 3 · Vol 0.30x

2026-10-08S4

Wk 3 · Vol 0.60x

2026-10-07S4

Wk 3 · Vol 0.81x

Moving averages & range

50 DMA

$6.41

200 DMA

$7.57

52W High

$11.68

52W Low

$2.87

5D Low

$4.97

Resistance levels (recent highs)

20d High

$6.43

60d High

$8.17

120d High

$11.26

250d High

$11.68

Next resistance

+29.4%

to 20d High

ROE

-431.4%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 1.4

LeonaBio: quick answers

What stage is LeonaBio in?

As of Oct 22, 2026, LeonaBio (LONA) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 21, 2026 and is in week 5. What the four stages mean

Is LeonaBio in an uptrend?

No. LeonaBio is in a Stage 4 downtrend. It trades 34.3% below its 200-day average, which is falling.

How far is LeonaBio from its 52-week high?

LeonaBio closed at $4.97 on Oct 22, 2026, 57.4% below its 52-week high of $11.68. Its 52-week low is $2.87.

How has LeonaBio performed over the past year?

As of Oct 22, 2026, LeonaBio is up 16.7% over the past year and down 28.6% so far in 2026.

Which sector and industry is LeonaBio in?

LeonaBio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer's disease and Parkinson's disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.